Effects of Oral L-Arginine on Chronic Hypertension in Pregnancy
NCT ID: NCT00571766
Last Updated: 2009-09-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
80 participants
INTERVENTIONAL
2007-11-30
2008-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
L-arginine Effects on Chronic Hypertension in Pregnancy
NCT00974714
L-Arginine in Pre-Eclampsia
NCT00157521
Role of L-citrulline in Prevention of Pregnancy Associated Hypertension
NCT04979793
Oral L-Citrulline and ADMA in Pregnancy
NCT00743210
L-Arginine Treatment for Severe Vascular Fetal Intrauterine Growth Restriction: a Randomized Double Bind Controlled Trial (L Arginine in IUGR)
NCT00549575
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Oral L-Arginine 2 g twice a day for 14 weeks
L-Arginine
Oral L-Arginine 2g, twice a day for 14 weeks
2
Placebo 2 g, twice a day for 14 weeks
Placebo
Placebo 2 g twice a day for 14 weeks
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
L-Arginine
Oral L-Arginine 2g, twice a day for 14 weeks
Placebo
Placebo 2 g twice a day for 14 weeks
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
40 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Modena and Reggio Emilia
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
University of Modena and Reggio Emilia
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Fabio Facchinetti, MD
Role: PRINCIPAL_INVESTIGATOR
University of Modena and Reggio Emilia
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Modena and Reggio Emilia
Modena, Emilia-Romagna, Italy
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Oral L-Arginine
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.